PUBLISHER: DelveInsight | PRODUCT CODE: 1381121
PUBLISHER: DelveInsight | PRODUCT CODE: 1381121
“"Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about lerapolturev + pembrolizumab for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the lerapolturev + pembrolizumab for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the lerapolturev + pembrolizumab for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the lerapolturev + pembrolizumab market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.
Lerapolturev (formerly known as PVSRIPO) is novel viral immunotherapy based on the Sabin type-1 polio vaccine and genetically modified so it is fully neuro-incompetent and cannot harm healthy cells. It has a natural affinity for CD155 antigens, specific surface markers abundant on GBM cells. CD155 is also expressed on antigen-presenting cells such as dendritic cells and macrophages. Unlike cancer cells with a weakened antiviral response, macrophages and dendritic cells exposed to PVSRIPO can limit viral replication and engage T cells. Thus, PVSRIPO targets tumors with two primary mechanisms: Direct damage and killing of cancerous cells and engaging innate and adaptive antitumor immune responses via sublethal infection of antigen-presenting cells in the tumor unleash an inflammatory cascade resulting in sustained systemic antitumor immunity.
Lerapolturev can be used as a treatment against many cancers as diverse tumor cells exhibit abundant surface expression of CD155. The company is currently conducting a Phase II (LUMINOS-101) clinical study investigating the safety and efficacy of lerapolturev in combination with pembrolizumab in rGBM.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of lerapolturev + pembrolizumab for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of lerapolturev + pembrolizumab for GBM covering trial interventions, trial conditions, trial status, start and completion dates.